Treatment adherence (proportion of days covered) by deprivation quintile in the Salford Lung Study (SLS) of COPD and SLS asthma (total study populations and SLS asthma inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy subset#)
| Deprivation quintile¶ | SLS COPD (n=2791) | SLS asthma (n=4218) | ICS/LABA therapy subset (n=2642) | ||||||
| Patients | FF/VI (n=1396) | UC (n=1395) | Patients | FF/VI (n=2105) | UC (n=2113) | Patients | FF/VI (n=1319) | UC (n=1323) | |
| 1 | 1423 | n=722 83.8±23.3 | n=701 82.6±23.0 | 848 | n=410 78.2±24.3 | n=438 78.9±25.4 | 546 | n=266 78.7±23.5 | n=280 76.6±25.4 |
| 2 | 587 | n=303 85.4±21.7 | n=284 83.1±22.9 | 829 | n=432 79.4±24.3 | n=397 79.0±25.5 | 522 | n=274 81.1±22.9 | n=248 78.2±25.5 |
| 3 | 386 | n=187 87.5±20.3 | n=199 81.1±22.3 | 849 | n=399 82.4±23.2 | n=450 79.9±24.6 | 545 | n=250 81.7±23.7 | n=295 77.8±25.0 |
| 4 | 206 | n=101 86.8±21.9 | n=105 80.4±24.7 | 823 | n=422 85.4±21.2 | n=401 77.2±25.7 | 505 | n=262 85.3±21.6 | n=243 76.1±25.5 |
| 5 | 131 | n=65 86.1±19.8 | n=66 84.6±25.3 | 833 | n=426 85.9±20.6 | n=407 75.8±27.6 | 497 | n=254 86.8±18.9 | n=243 73.7±28.1 |
Data are presented as mean±sd proportion of days covered (PDC) based on electronic case report form study medication prescribing data captured during the study, based on patients with available PDC data (n=2733 for SLS COPD; n=4182 for SLS asthma; n=2615 for SLS asthma ICS/LABA therapy subset). FF/VI: fluticasone furoate/vilanterol; UC: usual care. #: the SLS asthma ICS/LABA therapy subset comprised patients whose baseline maintenance therapy per randomisation stratification and pre-randomisation prescription was an ICS/LABA; ¶: where 1 is the most deprived and 5 is the least deprived.